Press Releases

Companies press releases

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017

CRANBURY, N.J., Sept. 25, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2017.  Recent and Fiscal Year Significant Highlights Bremelanotide […]

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results; Teleconference and Webcast to be held on September 25, 2017 Read More »

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2017 Results; Teleconference and Webcast to be held on September 25, 2017

CRANBURY, N.J., Sept. 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter and fiscal year end 2017 operating results on Monday, September 25, 2017  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2017 Results; Teleconference and Webcast to be held on September 25, 2017 Read More »

Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors

Sep 12, 2017, 07:30 ET CRANBURY, N.J., Sept. 12, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Anthony M. Manning, Ph.D. was appointed to Palatin’s Board of Directors on September 7,

Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors Read More »

Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories

CRANBURY, NJ, Sept. 6, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN; “Palatin”) announced today that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), for exclusive rights to develop and commercialize bremelanotide for female sexual

Palatin Technologies Announces Signing of Licensing Agreement with Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories Read More »

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017

May 16, 2017, 07:30 ET CRANBURY, N.J., May 16, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2017.  Quarter and Recent Highlights Bremelanotide –

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017 Read More »

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017

May 11, 2017, 07:30 ET CRANBURY, N.J., May 11, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2017 operating results on Tuesday, May 16, 2017  before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on May 16, 2017 Read More »

Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

CRANBURY, N.J., March 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial

Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women Read More »

Palatin Technologies To Present At The 29th Annual ROTH Conference

Mar 09, 2017, 15:00 ET CRANBURY, N.J., March 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 11:00 a.m. Pacific Time.  The conference will be held at The Ritz Carlton Laguna Niguel in Dana Point, CA.

Palatin Technologies To Present At The 29th Annual ROTH Conference Read More »

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017

CRANBURY, N.J., Feb. 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2016.  Recent Highlights Rekynda (bremelanotide) – Under development for Hypoactive Sexual Desire

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017 Read More »

Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™

Will Also Report Second Quarter 2017 Results and Discuss Next Steps in its Development Programs Teleconference and Webcast to be held on February 9, 2017 Feb 03, 2017, 06:00 ET CRANBURY, N.J., Feb. 3, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced the closing of its license agreement with AMAG Pharmaceuticals, Inc. (Nasdaq:

Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™ Read More »

Scroll to Top